Healthcare provider profile · identity verified

Daniel Martin Weisel, MD

Family Practice · O FALLON, MO · NPI 1629506522

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	573	187
Lisinopril	Lisinopril	343	107
Amlodipine Besylate	Amlodipine Besylate	340	107
Levothyroxine Sodium	Levothyroxine Sodium	255	97
Losartan Potassium	Losartan Potassium	217	75
Metoprolol Succinate	Metoprolol Succinate	209	73
Gabapentin	Gabapentin	190	58
Rosuvastatin Calcium	Rosuvastatin Calcium	189	61
Omeprazole	Omeprazole	186	70
Pantoprazole Sodium	Pantoprazole Sodium	182	59
Hydrochlorothiazide	Hydrochlorothiazide	144	50
Tamsulosin Hcl	Tamsulosin Hcl	132	46
Simvastatin	Simvastatin	117	45
Metformin Hcl	Metformin Hcl	115	44
Metformin Hcl Er	Metformin Hcl	112	37
Trazodone Hcl	Trazodone Hcl	105	42
Metoprolol Tartrate	Metoprolol Tartrate	104	33
Escitalopram Oxalate	Escitalopram Oxalate	102	34
Eliquis	Apixaban	99	27
Montelukast Sodium	Montelukast Sodium	99	28
Pravastatin Sodium	Pravastatin Sodium	87	33
Furosemide	Furosemide	81	34
Alprazolam	Alprazolam	78	37
Meloxicam	Meloxicam	69	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	68	40
Albuterol Sulfate Hfa	Albuterol Sulfate	67	30
Allopurinol	Allopurinol	66	23
Glipizide	Glipizide	63	18
Clopidogrel	Clopidogrel Bisulfate	61	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	59	27
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	16
Olmesartan Medoxomil	Olmesartan Medoxomil	55	16
Citalopram Hbr	Citalopram Hydrobromide	54	23
Famotidine	Famotidine	53	21
Glimepiride	Glimepiride	53	19
Prednisone	Prednisone	53	39
Duloxetine Hcl	Duloxetine Hcl	51	20
Finasteride	Finasteride	50	18
Alendronate Sodium	Alendronate Sodium	49	18
Fluoxetine Hcl	Fluoxetine Hcl	49	13
Fluticasone Propionate	Fluticasone Propionate	49	24
Irbesartan	Irbesartan	49	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	21
Carvedilol	Carvedilol	48	18
Celecoxib	Celecoxib	47	13
Spironolactone	Spironolactone	47	18
Arexvy	Rsvpref3 Antigen/As01e/Pf	46	46
Sertraline Hcl	Sertraline Hcl	46	18
Lorazepam	Lorazepam	45	16
Ezetimibe	Ezetimibe	43	17
Zolpidem Tartrate	Zolpidem Tartrate	43	11
Tramadol Hcl	Tramadol Hcl	41	18
Trulicity	Dulaglutide	41	suppressed
Jardiance	Empagliflozin	40	11
Ondansetron Odt	Ondansetron	40	18
Baclofen	Baclofen	34	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	31	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	suppressed
Meclizine Hcl	Meclizine Hcl	31	16
Mounjaro	Tirzepatide	30	11
Naproxen	Naproxen	29	15
Bupropion Xl	Bupropion Hcl	28	13
Clonidine Hcl	Clonidine Hcl	28	suppressed
Potassium Chloride	Potassium Chloride	28	14
Quetiapine Fumarate	Quetiapine Fumarate	28	suppressed
Buspirone Hcl	Buspirone Hcl	27	12
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	25	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	25	suppressed
Ketoconazole	Ketoconazole	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	20
Azithromycin	Azithromycin	22	21
Synthroid	Levothyroxine Sodium	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	11
Warfarin Sodium	Warfarin Sodium	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Glipizide Er	Glipizide	20	12
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Lidocaine	Lidocaine	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	11
Tizanidine Hcl	Tizanidine Hcl	20	13
Hydrocortisone	Hydrocortisone	19	11
Januvia	Sitagliptin Phosphate	19	suppressed
Atenolol	Atenolol	18	suppressed
Clonazepam	Clonazepam	18	suppressed
Methylprednisolone	Methylprednisolone	18	18
Mirtazapine	Mirtazapine	18	suppressed
Nitroglycerin	Nitroglycerin	18	14
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Midodrine Hcl	Midodrine Hcl	14	suppressed
Nabumetone	Nabumetone	14	suppressed
Ozempic	Semaglutide	14	suppressed
Temazepam	Temazepam	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Cephalexin	Cephalexin	13	12
Linzess	Linaclotide	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Topiramate	Topiramate	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Levofloxacin	Levofloxacin	11	11
Methocarbamol	Methocarbamol	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error